Dan Smith
Postes par

Dan Smith

Dan Smith est le Product Manager d'Advisor chez Planview. Avant d'occuper ce poste, il supervisait la sécurité de l'information et l'infrastructure applicative chez Enrich. Dan est titulaire d'un certificat d'études supérieures en gestion de l'ingénierie de l'université de Cambridge, d'un MBA de l'université de Santa Clara et d'une licence en génie mécanique de l'université de Pennsylvanie. Voyant la nourriture comme le carburant indispensable d'une entreprise, il met son temps libre à profit pour trouver des prétextes d'apporter des gâteaux et autres gourmandises au bureau.

Gestion de portefeuilles : adoptez une approche à la fois stratégique et adaptative

Pour une gestion de portefeuilles efficace, les leaders doivent trouver un équilibre entre la flexibilité de la planification à court terme et l'alignement stratégique. La plupart des plateformes de gestion de portefeuilles permettent de se concentrer sur l'une de ces compétences au détriment de l'autre. En effet, les organisations qui mettent l’accent sur la flexibilité peuvent dangereusement s'éloigner des objectifs stratégiques. A contrario, les organisations fixées sur la stratégie peuvent être trop rigides pour réagir aux contraintes à court terme.

Nouveaux défis en matière de gestion de portefeuille biopharmaceutique

En 2023, Planview a eu le plaisir de parrainer plusieurs événements du Sommet du WHY : Basilic, Suisse et Philadelphie. Un an plus tard, nous sommes retournés à Philadelphie, puis nous avons traversé le pays pour nous rendre à San Francisco afin d'assister à la 21e} et à la 22e} conférence américaine sur la gestion de projets, de programmes et de portefeuilles organisée par le WHY Summit. Dans ce blog, nous allons éclairer quelques...

Using EAP’s Project Prioritization Software to Allocate Technology Investments – Enrich Consulting

We’ve talked elsewhere about how EAP can provide sophisticated strategic resource planning and capacity planning. In those cases, the concerns were mostly around staffing—making sure key projects had the right people at the right time and anticipating and addressing staffing shortages. But other resources can benefit from this approach as well. Money, for instance—always needed...

R&D Portfolio Management for Pipeline Strategy – Enrich Consulting

The past several months have seen a flurry of dealmaking in pharma and biotech. Pfizer, having been rebuffed by AstraZeneca, bought a manufacturer of biosimilars, increasing speculation that the company is planning to split itself in two. Shire, similarly stung by its failed attempt to buy AbbVie, is buying NPS pharmaceuticals. A very public drama...

Sales Planning Software in Pharmaceuticals and Biotechs – Enrich Consulting

What is sales planning software? Sales planning software is used in the pharmaceutical and biotech industries to drive R&D, marketing, and manufacturing decisions both for in-market products and for medicines still in development. Functionally, it captures sales forecasts for each product in a company’s portfolio across geographies, patient segments, and product formulations. The forecasts are...

Project Prioritization is Not Enough: Why No One Uses Optimization for R&D Portfolio Management, and Why You Should – Enrich Consulting

R&D-driven organizations face the constant challenge of deciding whether to continue funding existing projects and when to start new initiatives. The overwhelming majority of firms will use project prioritization to rank the opportunities as part of that exercise, with a small minority suspecting that optimization is better suited to the task of project selection. So...

A Case of Mistaken Priorities: Project Prioritization Gone Bad – Enrich Consulting

It’s no secret that projects in the earlier stages of the development lifecycle are evaluated and managed very differently than projects in the later stages. One major pharmaceutical company believed these differences to be so great, however, that they split their development organization in two. Over time, the structural gulf became a cultural gulf, leading...

In R&D Portoflio Management, Failure is an Option – Enrich Consulting

Innovation is inherently risky. By definition, you’re doing something that you haven’t done before so there are no guarantees it will work. The mindset in many organizations is to “minimize” risk as if it were a disease, but it isn’t that simple. The best companies face risk head-on and manage it both systematically and transparently....

To Fund or Not to Fund: Helping Executives Get to “No” – Enrich Consulting

Another striking—and often underappreciated—aspect of [Steve] Jobs’ success was his ability to say no. At a company like Apple, thousands of ideas bubble up each year for new products and services that it could launch. The hardest thing for its leader is to decide which ones merit attention. Mr Jobs had an uncanny knack of...

Tied Up in Knots: Wasted Effort in R&D Portfolio Management – Enrich Consulting

“We can’t talk about the portfolio until you explain why Varmenase revenue is 5% less than last year’s forecast!” In almost every large organization a huge percentage of the effort in the “portfolio” process is spent “tying out” the new project valuations with the old ones. Teams ardently create reports to explain why the net present...